Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity [Phase 2]
Phase 2 trial evaluating atezolizumab in biomarker-selected patients across multiple cancer types; recruitment is ongoing. Tumors are select…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC [Phase 1]
A Phase 1 trial named DAPHNe is evaluating the combination of paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer. The st…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer [NA]
A clinical trial is evaluating RecurIndex-guided avoidance of regional nodal irradiation for node-positive breast cancer, and the study is c…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer [NA]
This ClinicalTrials.gov update notes that the trial evaluating intensity-modulated accelerated partial breast irradiation before surgery in …
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Chlorhydrate of Ropivacaine and Breast Cancer Surgery [Phase 4]
A Phase 4 clinical trial evaluating chlorhydrate of ropivacaine for breast cancer surgery has completed, per sponsor Institut Curie.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer [Phase 1]
First-in-human Phase 1 study of RLY-2608, a mutant-selective PI3Kα inhibitor, in adults with advanced solid tumors. The trial also evaluates…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Neurocognitive and Psychological Impact of Chemotherapy in Breast Cancer Patients: A Prospective Observational Study
A prospective observational study at Sohag University investigates the neurocognitive and psychological effects of chemotherapy in breast ca…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Cardiotoxicity in Breast Cancer Patients [Phase 4]
A Phase 4 clinical trial is recruiting to investigate cardiotoxicity in patients with breast cancer.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Single-Stage Prepectoral Placement of Textured Implants Using a Polyester Mesh Endoprostheses With Fluoropolymer Coating in Patients With Breast Cancer [NA]
Clinical trial update for a single-stage prepectoral placement of textured implants with a fluoropolymer-coated polyester mesh endoprosthesi…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction [NA]
Clinical trial update noting improved retrieval rate for HydroMARK Plus versus HydroMARK and higher surgeon satisfaction in breast biopsy si…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Physical Exercise During Preoperative Chemotherapy for Breast Cancer [NA]
Karolinska Institutet is conducting a clinical trial to evaluate physical exercise during preoperative chemotherapy for breast cancer; the s…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) [Phase 3]
A Phase 3 trial (SIMRISE) is evaluating SIM0270 in combination with everolimus versus physician's choice in ER+/HER2- advanced/metastatic br…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 [Phase 1]
Phase 1 study evaluating allogeneic natural killer cells with trastuzumab and pertuzumab for refractory metastatic HER2-positive breast canc…
-
CLINICAL_TRIALS other · 2025-09-22Clinical Trial Update: Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer. [NA]
The clinical trial evaluating the Medidux digital health application for HER2-positive breast cancer has been terminated.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer [NA]
This clinical trial update describes a study comparing web-based support to standard management to improve adherence to adjuvant hormone the…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer [NA]
This clinical trial update notes that the study on the impact of sleep disturbance on cognition and quality of life in breast cancer patient…
-
FDA approval · 2025-09-19FDA Approved: LEUPROLIDE ACETATE — Supplemental Application (Meitheal Pharmaceuticals Inc)
FDA approved a supplemental application for Leuprolide acetate from Meitheal Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial [Phase 3]
Phase III randomized trial comparing Hydrosorb to control for radiation-induced skin toxicity in breast cancer patients has completed.
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: TRUDI: TDXD+Durva in HER2+/Low IBC [Phase 2]
Phase 2 trial TRUDI is evaluating trastuzumab deruxtecan (TDXd) plus durvalumab (Durva) in HER2-positive and HER2-low invasive and inflammat…
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery [Phase 4]
Phase 4 double-blind trial comparing erector spinae block (ESP) to paravertebral block (PVB) for anesthesia in breast cancer surgery; the st…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer [Phase 3]
Phase 3 SONIA trial evaluating endocrine therapy plus a CDK4/6 inhibitor as first- or second-line treatment for hormone receptor-positive ad…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study [Phase 2]
Clinical trial update on the TRAIN-3 Phase 2 study evaluating image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Improving Comprehensive Care of Cancer Patients [NA]
A clinical trial update about a study aimed at improving comprehensive care for cancer patients, currently in recruitment.
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery [Phase 3]
Phase 3 trial comparing interpectoral nerve block with ropivacaine to placebo in breast cancer surgery has completed. The study evaluated an…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: From Exclusion to Inclusion: Analysing Follow-up Discontinuity in Breast Cancer
The article analyzes how exclusion and subsequent inclusion affect follow-up discontinuity in breast cancer trials. It discusses implication…